fluvastatin + benazepril

Fluvastatin + benazepril is a combination of two pharmaceutical agents, each with distinct mechanisms of action. Fluvastatin is a statin (HMG-CoA reductase inhibitor) that lowers cholesterol by inhibiting the enzyme responsible for cholesterol synthesis in the liver, thereby reducing low-density lipoprotein (LDL) cholesterol and overall cardiovascular risk. Benazepril is an angiotensin-converting enzyme (ACE) inhibitor that lowers blood pressure by blocking the conversion of angiotensin I to angiotensin II, leading to vasodilation and reduced aldosterone secretion. The combination would theoretically provide both antihypertensive and lipid-lowering effects, targeting two major cardiovascular risk factors.